MedTrace Logo

Interest of TEG6S® in Reducing Transfusion Needs During Postpartum Haemorrhage

NCT06473233 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 195

Last updated 2025-03-14

No results posted yet for this study

Summary

The main objective of this study is to evaluate fibrinogen consumption, transfusion need, and other security outcomes in women with postpartum hemorrhage of 1000 mL or more, before and after the implementation of a TEG6S® device at a level III maternity unit (Centre Hospitalier Sud Francilien, Corbeil-Essonnes, France).

Conditions

  • Postpartum Hemorrhage

Interventions

DEVICE

TEG6S

Hemostatic management including one or more delocalized biology test with the TEG6S®, at the discretion of the responsible clinician

Sponsors & Collaborators

  • Centre Hospitalier Sud Francilien

    lead OTHER

Principal Investigators

  • Fatima BRIK · Centre Hospitalier Sud Francilien

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-10-09
Primary Completion
2025-03-06
Completion
2025-03-06

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06473233 on ClinicalTrials.gov